A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Aref A Al-KaliIbrahim AldossPamela J AthertonCarrie A StrandBijal ShahJonathan WebsterBhavana BhatnagarKaren S FlattenKevin L PetersonPaula A SchneiderSarah A BuhrowJianping KongJoel M ReidAlex A AdjeiScott H KaufmannPublished in: Cancer medicine (2023)
In summary, single-agent sapanisertib had a good safety profile but limited target inhibition or efficacy in ALL as a single agent. This trial was registered at ClinicalTrials.gov as NCT02484430.